Lv2
126 积分 2024-06-13 加入
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
24天前
已完结
Zanubrutinib-lenalidomide-rituximab (ZR2) in unfit diffuse large B-cell lymphoma: efficient and tolerant
28天前
已完结
Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study
1个月前
已完结
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
1个月前
已完结
Survival benefit of adjuvant radiotherapy following asparaginase-based chemotherapy in patients with chemo-responsive advanced-stage extranodal NK/T-cell lymphoma: A multicenter study using the CLCG database
1个月前
已完结
Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: an ancillary study from the BLOCAGE trial
1个月前
已完结
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study
1个月前
已完结
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial
1个月前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2个月前
已完结
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
2个月前
已完结
皖公网安备34019202002308
